Moriya K, et al. - Researchers tested whether repeated hepatic arterial infusion chemotherapy (HAIC) given at eight-week intervals would be an efficacious treatment approach for the treatment of advanced hepatocellular carcinoma (HCC). Study participants were 66 compensated cirrhotic patients with advanced HCC refractory to transcatheter arterial chemo-embolization (TACE), of whom 21 were treated by bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) and the rest by sorafenib. They carried out a retrospective evaluation of the overall survival periods, curative responses, and adverse events in each group. They recommended B-HAIC be considered an alternative strategy for advanced HCC patients who do not respond to TACE, in view of the hepatic function reserve preservation afforded by the B-HAIC treatment in their experience.